Literature DB >> 11397705

Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women.

L K Heilbronn1, M Noakes, P M Clifton.   

Abstract

C-reactive protein (CRP) is an inflammatory-response protein that is a strong, independent predictor of cardiovascular mortality. CRP is positively associated with body mass index (BMI). In this study, we investigated the effects of dynamic weight loss on CRP in 83 healthy, obese women (mean BMI, 33.8+/-0.4 kg/m(2); range, 28.2 to 43.8 kg/m(2)). Subjects were placed on very-low-fat, energy-restricted diets (5700 kJ, 15% fat) for 12 weeks. Weight, waist and hip circumferences, plasma lipids, glucose, and CRP were measured at baseline and after 12 weeks. CRP was positively associated with BMI (r=0.281, P=0.01) and waist circumference (r=0.278, P=0.01) but was not related to other atherosclerosis risk factors. BMI was significantly different between groups split above or below the median for CRP (34.8+/-0.6 kg/m(2) vs 33.0+/-0.5 kg/m(2), P=0.02). After 12 weeks, weight loss was 7.9+/-0.3 kg. CRP was significantly decreased by 26% (P<0.001), and a correlation was observed between weight loss and the change in CRP (r=0.309, P=0.005). The variance in the change in CRP was partly explained by initial CRP (13.6%), energy intake (5.4%), and percentage weight loss (4.6%, P=0.001). This study confirms recent observations that BMI is associated with CRP, a marker for low-grade systemic inflammation. Furthermore, we observed that CRP was lowered in proportion to weight loss.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397705     DOI: 10.1161/01.atv.21.6.968

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  66 in total

Review 1.  Vascular inflammation as a therapeutic target for prevention of cardiovascular disease.

Authors:  Luther T Clark
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

Review 2.  Obesity, cytokines and endothelial dysfunction: a link for the raised cardiovascular risk associated with visceral obesity.

Authors:  K Esposito; G Nicoletti; D Giugliano
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

3.  Effect of diet with and without exercise training on markers of inflammation and fat distribution in overweight women.

Authors:  Gordon Fisher; Tanya C Hyatt; Gary R Hunter; Robert A Oster; Renee A Desmond; Barbara A Gower
Journal:  Obesity (Silver Spring)       Date:  2010-12-23       Impact factor: 5.002

Review 4.  An immune origin of type 2 diabetes?

Authors:  H Kolb; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

Review 5.  Adolescent-Onset Depression: Are Obesity and Inflammation Developmental Mechanisms or Outcomes?

Authors:  Michelle L Byrne; Neil M O'Brien-Simpson; Sarah A Mitchell; Nicholas B Allen
Journal:  Child Psychiatry Hum Dev       Date:  2015-12

Review 6.  Secretory leukocyte protease inhibitor promising protective roles in obesity-associated atherosclerosis.

Authors:  Qiao-Qing Zhong; Xiang Wang; Yun-Feng Li; Li-Jun Peng; Zhi-Sheng Jiang
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

Review 7.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

8.  Circulating markers of inflammation and their link to indices of adiposity.

Authors:  Lucy M Browning; Jeremy D Krebs; Edel C Magee; Gema Frühbeck; Susan A Jebb
Journal:  Obes Facts       Date:  2008-10-23       Impact factor: 3.942

9.  Parameters of inflammation in morbid obesity: lack of effect of moderate weight loss.

Authors:  Eva Solá; Ana Jover; Antonio López-Ruiz; María Jarabo; Amparo Vayá; Carlos Morillas; Marcelino Gómez-Balaguer; Antonio Hernández-Mijares
Journal:  Obes Surg       Date:  2008-12-03       Impact factor: 4.129

Review 10.  The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.

Authors:  Venkata Narla; Michael J Blaha; Roger S Blumenthal; Erin D Michos
Journal:  Vasc Health Risk Manag       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.